Alector (ALEC) News & Sentiment

Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.

Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates , including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m.

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m.

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration

Bank of America Securities has downgraded Alector, Inc.  ALEC, citing the failure of its AL002 program.

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002.

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.

OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.